These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24930676)

  • 1. An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
    Gurunath U; Joshi R; Agrawal A; Shah V
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):929-35. PubMed ID: 24930676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of Kala-Azar from the Southeast Asia Region.
    Bhattacharya SK; Dash AP
    Am J Trop Med Hyg; 2017 Apr; 96(4):802-804. PubMed ID: 28115678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can visceral leishmaniasis be eliminated from Asia?
    Joshi A; Narain JP; Prasittisuk C; Bhatia R; Hashim G; Jorge A; Banjara M; Kroeger A
    J Vector Borne Dis; 2008 Jun; 45(2):105-11. PubMed ID: 18592839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new strategy for elimination of kala-azar from rural Bihar.
    Thakur CP
    Indian J Med Res; 2007 Nov; 126(5):447-51. PubMed ID: 18160749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
    Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
    J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliminating visceral leishmaniasis in South Asia: the road ahead.
    Rijal S; Sundar S; Mondal D; Das P; Alvar J; Boelaert M
    BMJ; 2019 Jan; 364():k5224. PubMed ID: 30670453
    [No Abstract]   [Full Text] [Related]  

  • 8. Visceral leishmaniasis: elimination with existing interventions.
    Matlashewski G; Arana B; Kroeger A; Battacharya S; Sundar S; Das P; Sinha PK; Rijal S; Mondal D; Zilberstein D; Alvar J
    Lancet Infect Dis; 2011 Apr; 11(4):322-5. PubMed ID: 21453873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
    Chappuis F; Sundar S; Hailu A; Ghalib H; Rijal S; Peeling RW; Alvar J; Boelaert M
    Nat Rev Microbiol; 2007 Nov; 5(11):873-82. PubMed ID: 17938629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.
    Picado A; Rijal S; Sundar S; Boelaert M
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):839-41. PubMed ID: 23030320
    [No Abstract]   [Full Text] [Related]  

  • 13. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
    Salih NA; van Griensven J; Chappuis F; Antierens A; Mumina A; Hammam O; Boulle P; Alirol E; Alnour M; Elhag MS; Manzi M; Kizito W; Zachariah R
    Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the diagnosis and treatment of kala-azar.
    Sundar S; Chakravarty J
    Natl Med J India; 2012; 25(2):85-9. PubMed ID: 22686715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of visceral leishmaniasis on the Indian subcontinent.
    Singh OP; Hasker E; Boelaert M; Sundar S
    Lancet Infect Dis; 2016 Dec; 16(12):e304-e309. PubMed ID: 27692643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment.
    Sundar S; Mondal D; Rijal S; Bhattacharya S; Ghalib H; Kroeger A; Boelaert M; Desjeux P; Richter-Airijoki H; Harms G
    Trop Med Int Health; 2008 Jan; 13(1):2-5. PubMed ID: 18290995
    [No Abstract]   [Full Text] [Related]  

  • 20. Nonmigrant children with visceral leishmaniasis from the nonendemic area of Uttarakhand.
    Mathur SB; Arya AK
    J Trop Pediatr; 2014 Aug; 60(4):322-5. PubMed ID: 24531375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.